Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

A move to offer costly weight-loss drugs for obese Americans on Medicare and Medicaid may be in the works, but such a program may run into problems with voluntary participation and expense concerns.